Last reviewed · How we verify

NCT01236235: REMAIN

A Non Comparative Observational Study to Describe the Duration and Outcome of Treatment in Therapy naïve HIV Positive Patients Initiated on Atazanavir (ATV)/ Ritonavir (RTV)-Based Highly Active Antiretroviral Therapy (HAART) Regimens

Completed Last updated 4 September 2013
What this trial tests

trial in HIV in 525 participants. Completed in 1 July 2013.

Timeline
1 January 2011
Primary endpoint
1 July 2013
1 July 2013

Quick facts

Lead sponsorBristol-Myers Squibb
StatusCompleted
Study typeOBSERVATIONAL
Enrollment525
Start date1 January 2011
Primary completion1 July 2013
Estimated completion1 July 2013
Sites53 locations across Germany, Portugal, Spain

Conditions studied

Sponsor

Bristol-Myers Squibb — full company profile →

Who can join

18 and older, any sex, with HIV. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to describe long term (\> 96 weeks) efficacy and safety of Atazanavir-based regimens in real life setting.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study.
    Teófilo E, Rocha-Pereira N, Kuhlmann B, Antela A, et al · · 2016 · cited 3× · PMID 26899539 · DOI 10.1080/15284336.2015.1112494

Verify or expand the search:

Other recruiting trials for HIV

Currently open trials in the same condition.

Other Bristol-Myers Squibb trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01236235.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing